Overall, Neuralstem's commitment to innovation and their significant progress in the field of stem cell technology position them as a compelling investment opportunity. The confidence shown by the recent $7.50MPost-IPO Equity investment underscores the potential for substantial growth and impact in the biotechnology and healthcare sectors. As Neuralstem continues to make strides in the development and application of their neural stem cell technology, they are poised to deliver groundbreaking advancements in the treatment of central nervous system diseases, ultimately transforming the landscape of medical care and providing hope for countless individuals affected by these conditions.
Neuralstem, Inc.
Advancing stem cell technology to treat central nervous system diseases and deliver hope for incurable conditions.
Founded 1996
3 employees
Post-IPO Equity
Total: $39.86M
Biotechnology, Health Care
General Information
Company Name
Neuralstem, Inc.
Founded Year
1996
Employees
3
Industries
Biotechnology, Health Care
Funding Stage
Post-IPO Equity
BounceWatch is an independent company data service, not affiliated with Neuralstem, Inc.. To contact Neuralstem, Inc., visit neuralstem.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About Neuralstem, Inc.
Taxonomy: Stem Cell Technology, Biotherapeutics, Neural Stem Cells, Central Nervous System Diseases, Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS, Parkinson's Disease, Research and Development, Therapeutic Innovation, Medical Breakthroughs
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $7.50M | - |
|
31 Jul 2019 |
| Post IPO Equity | $20.00M | 1 |
|
12 Dec 2016 |
| Post IPO Equity | $1.08M | - |
|
23 May 2016 |
| Post IPO Equity | $1.78M | - |
|
10 Apr 2013 |
| Post IPO Debt | $8.00M | 1 |
|
25 Mar 2013 |
| Post IPO Equity | $1.50M | - |
|
05 Jan 2010 |
Neuralstem, Inc. Alternatives & Competitors
View All Alternatives
Neuralstem, Inc. vs
Medinno
Korea South
Expert of Cell Therapeutics for Brain Diseases
Series C
7 employees
Biotechnology, Health Care
Neuralstem, Inc. vs
Brainstorm Cell Therapeutics
Israel
BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenera...
Post-IPO Equity
36 employees
Biotechnology, Health Care
Neuralstem, Inc. vs
NeuExcell Therapeutics
United States
A Gene Therapy Company Leading Neural Regeneration and Repair
Seed
5 employees
Biotechnology, Health Care
FAQ About Neuralstem, Inc.
Advancing stem cell technology to treat central nervous system diseases and deliver hope for incurable conditions.
Neuralstem, Inc. was founded in 1996.
Neuralstem, Inc. operates in Biotechnology and Health Care. Its work centres on Stem Cell Technology, Biotherapeutics, Neural Stem Cells and Central Nervous System Diseases.
Neuralstem, Inc. has approximately 3 employees.
Neuralstem, Inc. has completed 6 funding rounds, raising a total of $39.86M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Neuralstem, Inc. include Medinno, Brainstorm Cell Therapeutics, NeuExcell Therapeutics, ReNetX Bio, Q Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neuralstem, Inc. and Medinno are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Neuralstem, Inc., https://bouncewatch.com/company/neuralstem, updated 25 October 2024. When citing, please name BounceWatch and link this page.
